Document:

Exhibit
10.19(c)

 

CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED.

 

TEXT
OMITTED FROM THIS EXHIBIT IS MARKED WITH [***]

 

AMENDMENT
NO. 2 TO LICENSE AGREEMENT

 

THIS
AMENDMENT NO. 2 TO LICENSE AGREEMENT (this “Amendment”), dated as of June 5th, 2012, amends that certain License
Agreement, dated June 28, 2000 (the “License Agreement”), further identified as USF LIC97018, between the UNIVERSITY
OF SOUTH FLORIDA RESEARCH FOUNDATION, INC., a Florida corporation not for profit under Chapter 617, Florida Statutes, and a direct
support organization of the University of South Florida (“RESEARCH FOUNDATION”), and IRX THERAPEUTICS, INC., a Delaware
corporation (“LICENSEE”). All capitalized terms appearing in this Amendment and not otherwise defined herein shall
have the meanings ascribed thereto in the License Agreement.

 

WHEREAS:

 

A.
The License Agreement was originally entered into by RESEARCH FOUNDATION and Immuno-Rx, Inc., a Florida corporation (the “Predecessor”),
and LICENSEE succeeded to the Predecessor’s rights and obligations under the License Agreement as a result of the migratory
merger of Predecessor with and into LICENSEE in August 2000.

 

B.
Upon the terms and conditions more particularly set forth in the License Agreement, the License Agreement provides for the grant
to LICENSEE of certain rights and licenses under any patents or patent applications related to USF Technology Reference No. 94A001
including the following:

 

1)
PCT Patent Application No. PCT/US10/59450 (USF Reference No. 11A098) filed on December 8, 2010 and entitled Method of Reversing
Immune Suppression of Langerhans Cells;

 

2)
PCT Patent Application No. PCT/US11/52139 (USF Reference No. 11A105) filed on September 19, 2011 and entitled Primary Cell-Derived
Biologic And WTI Synthetic Long Peptide Vaccine, and;

 

3)
U.S. Patent Application No. 13/320,584 (USF Reference number 11B138) filed on November 15, 2011 and entitled IRX2 - Vaccine
Immunotherapy, and all corresponding national filings as outlined in Appendix A.

 

C.
Simultaneous herewith, RESEARCH FOUNDATION, LICENSEE, and certain investors in LICENSEE are entering into a Royalty Sharing Agreement
pursuant to which RESEARCH FOUNDATION has agreed to share with such investors certain future royalty payments to be made to RESEARCH
FOUNDATION (the “Royalty Sharing Agreement”).

 

    	 

     

    

 

D.
In consideration of RESEARCH FOUNDATION entering into the Royalty Sharing Agreement, LICENSEE desires to hereby amend the License
Agreement to provide, upon the terms and conditions set forth in this Agreement, a royalty to RESEARCH FOUNDATION payable on gross
sales of Improvement Products and Improvement Processes (as defined below).

 

NOW,
THEREFORE, for good and valuable consideration, RESEARCH FOUNDATION and LICENSEE hereby agree as follows:

 

1.
Section 1.4 of the License Agreement is hereby amended by deleting said section in its entirety and replacing it with the following:

 

	 	1.4	“Licensed
    Product” and “Licensed Process” means:

 

	 	(i)	In
    the case of a Licensed Product, any product or part thereof, on a country-by-country basis:

 

	 	(1)	that
    is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Technology or the Patent
    Rights, in any country in which such product is made, used, imported or sold; or
	 	 	 
	 	(2)	that
    is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained
    in the Technology or the Patent Rights, in any country in which any such process is used or in which any such product is used,
    imported or sold; or
	 	 	 
	 	(3)	to
    the extent not described in foregoing clause (i)(1) or foregoing clause (i)(2), that is based upon, covered by, or utilizes
    any other invention, improvement, process, machine, method, manufacture, composition, or design described in any of the Improvement
    Patents or any foreign counterpart thereof (an “Improvement Product”); and

 

	 	(ii)	In
    the case of a Licensed Process, any process, on a country-by-country basis:

 

	 	(1)	that
    is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Technology or the Patent
    Rights in any country in which such process is practiced; or
	 	 	 
	 	(2)	to
    the extent not described in foregoing clause (ii)(1), that is based upon, covered by, or utilizes any other invention, improvement,
    process, machine, method, manufacture, composition, or design described in any of the Improvement Patents or any foreign counterpart
    thereof (an “Improvement Process”).

 

    	2

     

    

 

2.
Section 1.5 of the License Agreement is hereby amended by deleting said section it its entirety and replacing it with the following:

 

	 	1.5	“Improvement
    Patent” means the patents and patent applications listed on Appendix A hereto.”

 

	 	The
    document attached as Appendix A to this Amendment is hereby deemed to be added as Appendix B to the License Agreement.

 

3.
The License Agreement is hereby amended by adding the following as new Section 2.7 to the License Agreement:

 

	 	2.7	LICENSEE
    hereby represents and warrants to LICENSOR that the Patent Rights included in the Technology, together with the Improvement
    Patents, constitute all owned or in-licensed patents or patent applications of LICENSEE or its or subsidiaries or affiliates
    relevant or relating to the LICENSEE’s IRX-2 product as of the date of this Amendment (the “Applicable Product”).
    For purposes of Section 4.1 hereof, in the event that at any time during the Extension Period (as defined below) the Applicable
    Product is not based upon, covered by, or utilizing any invention, improvement, process, machine, method, manufacture, composition,
    or design described in any of the claims of an unexpired Improvement Patent, then such Applicable Product shall nevertheless
    be deemed to constitute an Improvement Product or Improvement Process, as applicable, through the end of the Extension Period.

 

4.
The first sentence of Section 4.1 of the License Agreement is hereby amended by deleting said sentence in its entirety and replacing
it with the following:

 

4.1
For the rights, privileges and license(s) granted hereunder, during the effective term of the patents upon which Patent Rights
are based and thereafter through the longer of (i) the effective term of the Improvement Patents or (ii) the date that is 4 years
and 180 days after the expiration of U.S. Patent No. 5,698,194, entitled Method for Making a Medicament for Treating Secondary
Immunodeficiency (such longer period referred to as the “Extension Period”), or until this Agreement shall otherwise
be sooner terminated as herein otherwise provided, LICENSEE shall pay RESEARCH FOUNDATION:

 

5.
Clauses (ii) and (iii) of Section 4.1(b) of the License Agreement are hereby amended by deleting said clauses in their entirety
and replacing them with the following:

 

	 	(ii)	sales
    of one hundred percent (100%) of the equity interests of LICENSEE, and (iii) sales of some lesser percentage of the equity
    interests of LICENSEE, in the nature of investments in LICENSEE.

 

6.
Section 13.4 of the License Agreement is hereby amended by adding the following language at the end of said section:

 

	 	However,
    such termination will in no event terminate LICENSEE’s obligation to pay the Running Royalties and License Fees on Improvement
    Products and Improvement Processes, as LICENSEE will, notwithstanding such termination, be obligated to pay the Running Royalties
    and License Fees on Improvement Products and Improvement Processes through the end of the Extension Period in accordance with
    the terms of this Agreement.

 

7.
Except as specifically set forth in this Amendment, all of the terms and provisions of the License Agreement shall continue to
remain in full force and effect.

 

8.
This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which
together shall constitute one document. This Amendment, together with the License Agreement, contains the final, complete, and
exclusive expression of the parties’ understanding and agreement concerning the matters contemplated herein and supersedes
any prior or contemporaneous agreement of representation, oral or written, among them with respect to such matters. This Amendment
shall be governed by, and construed and enforced in accordance with, the laws of the State of Florida (U.S.A.) without reference
to principles of choice of law thereunder.

 

    	 	3	 

     

    

 

IN
WITNESS WHEREOF, the parties have caused their respective signature page to this Amendment to be duly executed as of the date
first written above.

 

	UNIVERSITY OF SOUTH FLORIDA RESEARCH FOUNDATION, INC.
	 	 	 
	/s/
    Valerie Landrio McDevitt	 	Date:
9/17          , 2012
	 	 	 
	Valerie
    Landrio McDevitt, Assistant Vice President	 	 
	 	 	 
	Division
    of Patents & Licensing	 	 
	 	 	 
	IRX
    THERAPEUTICS, INC.	 	 
	 	 	 
	John
    W. Hadden, II	 	Date:
    July 19, 2012
	John
    W. Hadden,II	 	 
	President
    & CEO	 	 

 

    	4

     

    

 

APPENDIX
A

 

[***]

 

    	5Exhibit
10.20

 

CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED.

 

TEXT
OMITTED FROM THIS EXHIBIT IS MARKED WITH [***]

 

EXECUTION

JUNE
22,2018

 

TERMINATION
AND LICENSE AGREEMENT

 

This
TERMINATION AND LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of June 22,
2018 (the “Effective Date”) by and among Celgene Corporation, a Delaware corporation (“Celgene”),
and IRX Therapeutics, Inc., a Delaware corporation (“Licensee”). Licensee and Celgene are each referred
to herein by name or as a “Party” or, collectively, as the “Parties.”

 

RECITALS

 

WHEREAS,
the Parties entered into that certain Research, Development and Option Facilitation Agreement dated as of April 24, 2014 (the
“RDO Agreement”) pursuant to which, among other things, Licensee agreed to advance the development of certain
product candidates in collaboration with Celgene;

 

WHEREAS,
pursuant to the RDO Agreement, Celgene paid Licensee [***] U.S. Dollars ($[***]) in consideration of rights granted to Celgene
under the RDO Agreement;

 

WHEREAS,
concurrently with the execution and delivery of the RDO Agreement, Celgene entered into an option agreement with certain Licensee
stockholders and holders of securities convertible into Licensee capital stock (such agreement is the “Option Agreement”
and such parties, the “Sellers”), pursuant to which the Sellers granted an option to Celgene to purchase
from the Sellers all securities in Licensee;

 

WHEREAS,
pursuant to the Option Agreement, Celgene paid Licensee [***] U.S. Dollars ($[***]) in consideration of rights granted to
Celgene under the Option Agreement;

 

WHEREAS,
Celgene and Licensee now desire to terminate the RDO Agreement and, upon such termination, the Option Agreement will also
automatically terminate;

 

WHEREAS,
in connection with such termination, the rights granted to Celgene under the RDO Agreement and the Option Agreement will also
terminate and neither Licensee nor the Sellers shall have any obligation to refund to Celgene either of the above-referenced payments.

 

NOW,
THEREFORE, in consideration of the foregoing and the mutual agreements set forth below, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

    	 

     

    

 

ARTICLE
1

DEFINITIONS

 

Capitalized
terms used, but not defined, herein will have the meanings ascribed to them in the RDO Agreement.

 

1.1
“Accounting Standards” means (a) United States Generally Accepted Accounting Principles (“GAAP”);
or (b) to the extent that a Party adopts International Financial Reporting Standards (“IFRS”), then “Accounting
Standards” means IFRS, in either case consistently applied.

 

1.2
“Affiliates” means person or entity which, directly or indirectly through one or more intermediaries, controls,
is controlled by or is under common control with a Party to this Agreement. For purposes of this definition, the term “control”
(including, with correlative meanings, the terms “controlled by” and “under common control with”) as used
with respect to a person or entity means (a) direct or indirect ownership of fifty percent (50%) or more of the voting securities
or other voting interest of any person or entity (including attribution from related parties), or (b) the possession, directly
or indirectly, of the power to direct or cause the direction of the management and policies of such person or entity, whether
through ownership of voting securities, by contract, as a general partner, as a manager, or otherwise.

 

1.3
“Annual Net Sales” means [***].

 

1.4
“Confidential Information” means, with respect to a Party, all non-public, confidential and proprietary information
and materials, including know-how, marketing plans, strategies, and customer lists, in each case, that are disclosed by such Party
to the other Party, regardless of whether any of the foregoing are marked “confidential” or “proprietary”
or communicated to the other Party by the disclosing Party in oral, written, visual, graphic or electronic form.

 

1.5
“First Commercial Sale” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the
first sale of such Licensed Product in such country for use or consumption by the general public for which any which all regulatory
approvals that are legally required in order to sell such Licensed Product in such country have been granted in each case; provided,
however, that the following shall not constitute a First Commercial Sale: (a) any sale to an Affiliate or Sublicensee unless the
Affiliate or Sublicensee is the last entity in the distribution chain of the Licensed Product; (b) any use of such Licensed Product
in clinical trials or non-clinical development activities with respect to such Licensed Product by or on behalf of Licensee, or
disposal or transfer of such Licensed Product for a bona fide charitable purpose; and (c) compassionate use; in each case of clauses
(a) — (c) for which no payment is received by Licensee, its Affiliates or Sublicensees.

 

1.6
“Licensed Field” means any use or purpose, including the treatment, palliation, diagnosis or prevention of
any human or animal disease, disorder or condition.

 

1.7
“Licensed Product” means any pharmaceutical product that constitutes, incorporates, comprises or contains the
compound designated IRX-2 (as further described on Exhibit A attached hereto), whether or not as the sole active ingredient, and
in all forms, presentations, and formulations (including manner of delivery and dosage).

 

    	2

     

    

 

1.8
“Net Sales” means, [***]:

 

(a)
[***];

 

(b)
[***];

 

(c)
[***];

 

(d)
[***];

 

(e)
[***]; and

 

(f)
[***].

 

[***]

 

As
used in this definition of “Net Sales,” “License Combination Product” means a Licensed Product
that contains one or more additional active ingredients (whether co-formulated or co-packaged) that are neither Licensed Candidates
nor generic or other non-proprietary compositions of matter. Pharmaceutical dosage form vehicles, adjuvants and excipients shall
be deemed not to be “active ingredients.”

 

1.9
“Regulatory-Based Exclusivity” means, on a Licensed Product-by-Licensed Product and country-by-country basis,
that (a) Licensee or any of its Affiliates or Sublicensees has been granted the exclusive legal right by a Regulatory Authority
(or is otherwise entitled to the exclusive legal right by operation of Law) in such country to market and sell the Licensed Product
and that no other entity can be granted the right to market and sell any other product comprising the same active ingredient as
is included in the Licensed Product in such country, including any pediatric or orphan drug exclusivity, or (b) the data and information
submitted by Licensee or any of its Affiliates or Sublicensees to the relevant Regulatory Authority in such country for purposes
of obtaining Regulatory Approval for such Licensed Product may not be disclosed, referenced or relied upon in any way by any Person
other than Licensee, its Affiliates or Sublicensees (including by relying upon the Regulatory Authority’s previous findings
regarding the safety or effectiveness of the Licensed Product) to support the Regulatory Approval or marketing of any product
by a Third Party in such country.

 

1.10
“Royalty Term” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period of
time commencing on the First Commercial Sale of such Licensed Product in such country and expiring upon the last to occur of:
(a) the twelfth (12th) anniversary of the date of First Commercial Sale of such Licensed Product in such country; (b)
the expiration, invalidation or abandonment date of the last IRX Patent (an updated list of which is attached hereto as Exhibit
B) that covers the manufacture, use or sale of such Licensed Product in such country; or (c) the expiration of Regulatory-Based
Exclusivity for such Licensed Product in such country.

 

    	3

     

    

 

1.11
“Sublicensees” means any person or entity that Licensee grants a sublicense of rights granted under this Agreement
to make, use, sell, offer for sale, have sold or import a Licensed Product.

 

1.12
“Territory” means worldwide.

 

ARTICLE
2

TERMINATION

 

2.1
Termination.

 

2.1.1
Termination of RDO Agreement. The Parties hereby mutually agree to terminate the RDO Agreement. The Parties hereby agree that
such termination is effective as of the Effective Date. The Parties further acknowledge that the effects of such termination of
the RDO Agreement shall be as set forth in Sections 11.7 and 11.8 of the RDO Agreement. For the avoidance of doubt, pursuant to
Section 11.7 of the RDO Agreement, all Confidential Information relating specifically to the Initial Development Plan (as defined
in the RDO Agreement), as amended and in effect as of the Effective Date, will be the Confidential Information (as defined in
the RDO Agreement) of Licensee and Licensee shall thereafter be free to use such Confidential Information without accounting or
obligation to Celgene.

 

2.1.2
Acknowledgement of Option Termination. The Parties hereby acknowledge that, pursuant to Section 10.5 of the Option Agreement,
the Option Agreement is terminated as of the Effective Date. The Parties further acknowledge that the effects of such termination
shall be as set forth in Section 10.7 of the Option Agreement.

 

ARTICLE
3

INTELLECTUAL PROPERTY

 

3.1
License. Celgene hereby grants an exclusive license, with the right to grant sublicenses through multiple tiers, under
all of Celgene’s right, title and interest in and to any and all Joint Inventions, to Licensee, to make, use, sell, offer
for sale, have sold and import Licensed Products throughout the Licensed Territory during the Term.

 

ARTICLE
4

FINANCIAL TERMS

 

4.1
Royalties.

 

4.1.1
Licensed Product Royalties. As consideration for the rights and terminations granted to Licensee herein, commencing upon
the First Commercial Sale of a Licensed Product in the Territory, Licensee shall pay to Celgene royalties on Annual Net Sales,
on a Licensed Product-by-Licensed Product and country-by-country basis during each calendar year, equal to [***] percent ([***]%)
of Annual Net Sales for each such Licensed Product in each such country during the applicable Royalty Term.

 

4.1.2
Royalty Term. Licensee’s royalty obligations to Celgene under Section 4.1 shall be on a Licensed Product-by-Licensed
Product and country-by-country basis for the applicable Royalty Term for such Licensed Product in such country. Only one royalty
shall be payable by Licensee to Celgene for each sale of a Licensed Product.

 

    	4

     

    

 

4.1.3
Payment of Royalties. Licensee shall: (a) within forty-five (45) days following the end of each calendar quarter after
the First Commercial Sale of a Licensed Product, provide to Celgene a report for each country in the Territory in which sales
of such Licensed Product occurred in the calendar quarter covered by such statement, specifying for such calendar quarter: the
number of Licensed Products sold; the gross sales and Annual Net Sales in each country’s currency; the applicable royalty
rate under this Agreement; the royalties payable in each country’s currency, including an accounting of deductions taken
in the calculation of Annual Net Sales in accordance with Accounting Standards; the applicable exchange rate to convert from each
country’s currency to U.S. Dollars under Section 4.2.1; and the royalty calculation and royalties payable in U.S. Dollars,
and (b) make the royalty payments owed to Celgene hereunder in accordance with such royalty report in arrears, within sixty (60)
days from the end of each calendar quarter in which such payment accrues. Licensee shall provide backup and supporting documentation
to Celgene for the reports and payments described herein upon Celgene’s reasonable request. If any payment due to Celgene
under this Agreement is not paid when due, then Licensee shall pay interest thereon (before and after any judgment) at an annual
rate (but with interest accruing on a daily basis) of two hundred (200) basis points above LIBOR or its designated successor,
such interest to run from the date on which payment of such sum became due until payment thereof in full together with such interest.

 

4.2
Additional Payment Terms.

 

4.2.1
Accounting. All payments hereunder shall be made in the United States in U.S. Dollars by wire transfer to a bank in the
U.S. designated in writing by Celgene. Conversion of sales recorded in local currencies to U.S. Dollars shall be performed in
a manner consistent with Licensee’s normal practices in accordance with the Accounting Standards consistently applied and
reflected in its audited financial statements for internal and external reporting purposes.

 

4.2.2
Tax Withholding.

 

(a)
Tax Withholding. Licensee shall be entitled to deduct and withhold from any amounts payable under this Agreement such taxes
as are required to be deducted or withheld therefrom under any provision of applicable Law. Licensee will: (i) deduct those taxes
from such payment, (ii) timely remit the taxes to the proper taxing authority, and (iii) send evidence of the obligation together
with proof of tax payment to Celgene on a timely basis following that tax payment; provided, however, that before making any such
deduction or withholding, Licensee shall give Celgene notice of the intention to make such deduction or withholding (such notice,
which shall include the authority, basis and method of calculation for the proposed deduction or withholding, shall be given at
least a reasonable period of time before such deduction or withholding is required, in order for Licensee to obtain reduction
of or relief from such deduction or withholding). Each Party agrees to cooperate with the other Party in claiming refunds or exemptions
from such deductions or withholdings under any relevant agreement or treaty which is in effect to ensure that any amounts required
to be withheld pursuant to this Section 4.2.2(a) are reduced in amount to the fullest extent permitted by applicable Laws. In
addition, the Parties shall cooperate in accordance with applicable Laws to minimize indirect taxes (such as value added tax,
sales tax, consumption tax and other similar taxes (“Indirect Taxes”)) in connection with this Agreement.

 

    	5

     

    

 

(b)
Tax Gross-up. Notwithstanding the foregoing, and subject to Section 4.2.2(c), if (i) a Licensee (or its assignee pursuant
to Section 7.3) redomiciles or assigns its rights or obligations under this Agreement pursuant to Section 7.3 after the Effective
Date, (ii) as a result of such redomiciliation or assignment, Licensee (or its assignee pursuant to Section 7.3) is required by
applicable Law to withhold taxes, or if such action results in the imposition of Indirect Taxes that were not otherwise applicable,
from or in respect of any amount payable under this Agreement or any other agreement entered into pursuant to this Agreement,
and (iii) such withholding taxes or Indirect Taxes exceed the amount of withholding taxes or Indirect Taxes that would have been
applicable if such redomiciliation or assignment had not occurred, then any such amount payable shall be increased to take into
account such increased withholding taxes or Indirect Taxes so that, after making all required withholdings (including withholdings
on the withheld amounts) and/or paying such Indirect Taxes, as the case may be, Celgene (or its assignee pursuant to Section 7.3)
receives an amount equal to the sum it would have received had such redomiciliation or assignment not occurred; provided, however,
that Licensee will have no obligation to pay any additional amount under the immediately preceding clause to the extent that such
increased withholding tax or such Indirect Taxes would not have been imposed but for the failure by Licensee to comply with the
requirements of Section 4.2.2(c). The additional amounts payable pursuant to this Section 4.2.2(b) shall be reduced by the amount
of any foreign tax credit, tax refund or similar item available to Celgene in respect or as a result of withholding taxes or Indirect
Taxes for which additional amounts have been paid pursuant to this Section 4.2.2(b), as mutually determined by the Parties cooperating
in good faith.

 

(c)
Tax Documentation. Celgene has provided a properly completed and duly executed IRS Form W-9 to Licensee. Celgene shall,
to the extent it is legally entitled to, provide to Licensee, at the time or times reasonably requested by Licensee or as required
by applicable Law, such properly completed and duly executed documentation (for example, IRS Forms W-8 or W-9) as will permit
payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes.

 

4.3
Records Retention by Licensee; Review by Celgene.

 

4.3.1
Records. Licensee shall, and shall cause its Affiliates and Sublicensees to, keep complete and accurate books and records
pertaining to Net Sales of Licensed Products, in sufficient detail to calculate all amounts payable hereunder and to verify compliance
with its obligations under this Agreement. Such books and records shall be retained by Licensee and its Affiliates and Sublicensees
until the later of (i) four (4) years after the end of the period to which such books and records pertain, and (ii) the expiration
of the applicable tax statute of limitations (or any extensions thereof), or for such longer period as may be required by Applicable
Law.

 

    	6

     

    

 

4.3.2
Audit. At the request of Celgene, Licensee shall, and shall cause its Affiliates and Sublicensees to, permit an independent
public accounting firm of nationally recognized standing designated by Celgene, at reasonable times during normal business hours
and upon reasonable notice, to audit the books and records maintained pursuant to Section 4.3.1 to ensure the accuracy of all
reports and payments made hereunder. Such examinations may not (i) be conducted for any calendar quarter more than four (4) years
after the end of such quarter, (ii) be conducted more than once in any twelve (12) month period (unless a previous audit during
such twelve (12)-month period revealed an underpayment with respect to such period) or (iii) be repeated for any calendar quarter.
The accounting firm shall disclose only whether the reports are correct or not and the specific details concerning any discrepancies.
No other information shall be shared. Except as provided below, the cost of this audit shall be borne by Celgene, unless the audit
reveals a variance of more than [***] percent ([***]%) from the reported amounts, in which case Licensee shall bear the cost of
the audit. If such audit concludes that (x) additional amounts were owed by Licensee, Licensee shall pay the additional amounts,
with interest from the date originally due at a rate prescribed by Section 4.1.3, or (y) excess payments were made by Licensee,
Celgene shall reimburse such excess payments, in either case ((x) or (y)), within sixty (60) days after the date on which such
audit is completed by Celgene.

 

ARTICLE
5

INDEMNIFICATION;
INSURANCE

 

5.1
Indemnification by Licensee. Licensee shall indemnify, defend and hold harmless the Celgene Indemnitees, from and against
any and all Third Party Damages to the extent arising out of or relating to, directly or indirectly, from any Claim based upon:

 

(a)
the gross negligence or willful misconduct of Licensee or its Affiliates and its or their respective directors, officers, employees
and agents, in connection with Licensee’s performance of its obligations or exercise of its rights under this Agreement;

 

(b)
any breach of any representation, warranty, covenant, agreement or obligation under this Agreement; or

 

(c)
the Development, Manufacture and/or Commercialization by or on behalf of Licensee, its Affiliate or Sublicensee of any Licensed
Product in the Territory, including any Product Liability claims in the Territory or any personal injury, property damage or other
damage in the Territory, in each case, resulting from any of the foregoing activities described in this Section 5.1(c).

 

5.2
[Intentionally omitted.]

 

5.3
Notice of Claims. A Claim to which indemnification applies under Section 5.1 shall be referred to herein as an “Indemnification
Claim.” If the Celgene Indemnitee intends to claim indemnification under this ARTICLE 5, the Party claiming indemnification
(the “Indemnitee”) shall notify Licensee (the “Indenmitor”) in writing, promptly upon becoming
aware of an Indemnification Claim, describing in reasonable detail the facts giving rise to the Indemnification Claim; provided,
that an Indemnification Claim in respect of any action at law or suit in equity by or against a Third Party as to which indemnification
shall be sought shall be given promptly after the action or suit is commenced (provided that the Indemnitee is aware of such commencement);
and provided further, that the failure by an Indemnitee to give such notice shall not relieve the Indemnitor of its indemnification
obligation under this Agreement except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure
to give notice.

 

    	7

     

    

 

5.4
Indemnification Procedures. If a Celgene Indemnitee receives written notice of a Claim that the Celgene Indemnitee believes
may result in a claim for indemnification under this ARTICLE 5, such Celgene Indemnitee shall deliver an Indemnification Claim
to Licensee in accordance with the provisions of Section 5.3. If the Litigation Conditions are satisfied, then Licensee shall
have the right to assume and control the defense of the Claim, at its own expense with counsel selected by it and reasonably acceptable
to the Celgene Indemnitee, by delivering written notice of its assumption of such defense to the Celgene Indemnitee within twenty
(20) days of its receipt of notice of such Claim from Licensee (but Licensee shall in any event have the right to assume and control
the defense of a Claim that initially sought injunctive relief (including a declaratory judgment) from the Celgene Indemnitee
when the only remaining dispute in such matter is the determination of non-injunctive relief or when the only remaining relief
sought by the Third Party in such matter is non-injunctive relief, whichever is first); provided, however, that the Celgene Indemnitee
shall have the right to retain its own counsel, with the reasonable fees and expenses to be paid by Licensee, if (a) representation
of the Celgene Indemnitee by the counsel retained by Licensee would be inappropriate due to actual or potential conflict of interests
between such Celgene Indemnitee and Licensee, (b) Licensee has failed within a reasonable time to retain counsel, (c) the Celgene
Indemnitee shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition
to those available to Licensee, or (d) at any time the Litigation Conditions are not satisfied with respect to such Claim. If
Licensee assumes and controls the defense of such Claim, Licensee shall keep the Celgene Indemnitee reasonably apprised of the
status of the Claim and the Celgene Indemnitee shall be entitled to otherwise monitor such Claim at its sole cost and expense.
If the Claim seeks injunctive relief (including a declaratory judgment) against or from the Celgene Indemnitee or if Licensee
does not assume the defense of the Claim as described in this Section 5.4, the Celgene Indemnitee shall be permitted to assume
and control the defense of such Claim (but shall have no obligation to do so) and in such event shall be entitled to settle or
compromise the Indemnification Claims in its sole and reasonable discretion, provided that if the Celgene Indemnitee is entitled
to assume the defense of the Claim pursuant to this Section 5.4 solely because the Claim seeks injunctive relief (including a
declaratory judgment) against or from the Celgene Indemnitee, then the Celgene Indemnitee shall not settle or compromise such
Indemnification Claims in any manner that involves the payment of monetary damages or has an adverse effect on Licensee’s
rights or interests (including any rights under this Agreement or the scope or enforceability of any Patents or Know-How licensed
by one Party to another Party pursuant to this Agreement or the RDO Agreement or the Option Agreement) without the prior written
consent of Licensee, which consent Licensee shall not unreasonably withhold, condition or delay. If Licensee has assumed and controls
the defense of the Claim in accordance with this Section 5.4, (i) the Celgene Indemnitee shall not settle or compromise the Indemnification
Claim without the prior written consent of Licensee, such consent not to be unreasonably withheld, conditioned or delayed and
(ii) Licensee shall not settle or compromise the Indemnification Claim in any manner that would result in the payment of amounts
by the Celgene Indemnitee, impose any other obligation on the Celgene Indemnitee or otherwise have an adverse effect on the Celgene
Indemnitee’s rights or interests (including any rights under this Agreement or the scope or enforceability of any Patents
or Know-How licensed by one Party to another Party pursuant to this Agreement or the RDO Agreement, or the Option Agreement),
without the prior written consent of the Celgene Indemnitee. In each case, the Party that is not controlling the defense of any
Claim shall reasonably cooperate with the Party that is controlling the defense of such Claim, at the non-controlling Party’s
expense and shall make available to the controlling Party all pertinent information under the control of the non-controlling Party.
Each Party shall use commercially reasonable efforts to avoid production of Confidential Information of the other Party (consistent
with applicable Law and rules of procedure), and to cause all communications among employees, counsel and other representatives
of such Party to be made so as to preserve any applicable attorney-client or work-product privileges.

 

    	8

     

    

 

5.5
Insurance. Licensee shall maintain, at Licensee’s cost, a program of insurance against liability and other risks
associated with its activities and obligations under this Agreement, including as applicable Licensee’s Clinical Trials,
the Commercialization of any Licensed Candidate, and Licensee’s indemnification obligations hereunder, in such amounts and
subject to such deductibles and on such terms as are customary for prudent practices for biotech companies of similar size and
with similar resources in the pharmaceutical industry for the activities to be conducted by Licensee under this Agreement, taking
into account the scope of development of products and the activities to be conducted by Licensee under this Agreement.

 

5.6
LIMITATION OF LIABILITY. EXCEPT (A) FOR A MATERIAL UNCURED BREACH OF SECTION 7.1 (CONFIDENTIALITY), OR (B) FOR CLAIMS THAT
ARE SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 5, OR (C) FOR DAMAGES DUE TO FRAUD, MALICIOUS ACTIONS AND/OR INTENTIONAL TORT
OF THE LIABLE PARTY, NEITHER CELGENE NOR LICENSEE, NOR ANY OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE TO THE OTHER PARTY TO
THIS AGREEMENT OR ITS AFFILIATES UNDER THIS AGREEMENT FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE OR EXEMPLARY
DAMAGES OR LOST PROFITS OR LOST DATA, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT
LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED
OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE.

 

ARTICLE
6

LICENSE TERM AND TERMINATION

 

6.1
License Term; Expiration.

 

6.1.1
License Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this
ARTICLE 6, shall remain in effect until it expires (the “License Term”):

 

(a)
on a Licensed Product-by-Licensed Product and country-by-country basis, this Agreement shall expire on the date of the expiration
of all applicable Royalty Terms with respect to such Licensed Product in such country; and

 

(b)
in its entirety upon the expiration of all applicable Royalty Terms under this Agreement with respect to all Licensed Products
in all countries in the Territory.

 

    	9

     

    

 

6.1.2
Effect of Expiration. After the expiration of the License Term pursuant to Section 6.1.1 above, the following terms shall
apply:

 

(a)
Licenses after Licensed Product Expiration. After expiration of the License Term (but not after early termination) with
respect to any Licensed Product in a country in the Territory pursuant to Section 6.1.1(a), Licensee shall have (i) an exclusive,
fully-paid, royalty-free, irrevocable, non-terminable, worldwide right and license, with the right to grant sublicenses, under
the Product IP, Celgene’s interest in Joint Collaboration IP, and Celgene’s interest in Collaboration IP and (ii)
a non-exclusive, fully-paid, royalty-free, irrevocable, non-terminable, worldwide right and license, with the right to grant sublicenses,
under the Platform IP, in each case of (i) and (ii) to Develop, Manufacture, have Manufactured, use, offer for sale, sell, import
and otherwise Commercialize such Licensed Product and related Licensed Diagnostic Products in the Licensed Field in such country
in the Territory, for so long as it continues to do so.

 

(b)
Licenses after Expiration of License Agreement. After expiration of the License Term (but not after early termination)
with respect to this Agreement in its entirety pursuant to Section 6.1.1(b), Licensee shall have (i) an exclusive, fully-paid,
royalty-free, irrevocable, non-terminable, worldwide right and license, with the right to grant sublicenses, under the Product
IP, Celgene’s interest in Joint Collaboration IP, and Celgene’s interest in Collaboration IP and (ii) a non-exclusive,
fully-paid, royalty-free, irrevocable, non-terminable, worldwide right and license, with the right to grant sublicenses, under
the Platform IP, in each case of (i) and (ii) to Develop, Manufacture, have Manufactured, use, offer for sale, sell, import and
otherwise Commercialize Licensed Products and Licensed Diagnostic Products in the Licensed Field in the Territory, for so long
as it continues to do so.

 

6.2
[Intentionally deleted.]

 

6.3
Termination for Breach.

 

6.3.1
Termination by Either Party for Breach. This Agreement and the rights granted herein may be terminated by either Party
for the material breach by the other Party of this Agreement, provided, that if the breaching Party has not cured such breach
within sixty (60) days (or thirty (30) days, in the case of Licensee’s payment obligations under this Agreement) (the “Cure
Period”) after the date of written notice to the breaching Party of such breach, which notice shall describe such breach
in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement pursuant to this Section
6.3.1. Any such termination of this Agreement under this Section 6.3.1 shall become effective at the end of the Cure Period, unless
the breaching Party has cured any such breach or default prior to the expiration of such Cure Period, or, if such breach is not
susceptible to cure within the Cure Period, then, the non-breaching Party’s right of termination shall be suspended only
if and for so long as the breaching Party has provided to the non-breaching Party a written plan that is reasonably calculated
to effect a cure and such plan is acceptable to the non-breaching Party, and the breaching Party commits to and carries out such
plan as provided to the non-breaching Party. The Parties understand and agree that the totality of this Agreement and the totality
of the circumstances with respect to this Agreement will be taken into account and assessed as a whole for purposes of determining
whether a breach is material under this Agreement.

 

    	10

     

    

 

6.3.2
Disagreement as to Material Breach. If the Parties reasonably and in good faith disagree as to whether there has been a
material breach pursuant to Section 6.3.1, then the Party that disputes that there has been a material breach may contest the
allegation pursuant to terms set forth in Article 12 of the RDO Agreement as if such terms were set forth herein in their entirety.

 

6.4
Termination for Bankruptcy. If either Party makes a general assignment for the benefit of creditors, appoints or suffers
appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency
act or has any such petition filed against it which is not dismissed, discharged, bonded or stayed within ninety (90) days after
the filing thereof, the other Party may terminate this Agreement in its entirety, effective immediately upon written notice to
such Party.

 

6.5
Effects of Expiration or Termination.

 

6.5.1
License Upon Expiration. Upon expiration (but not upon earlier termination) of this Agreement, the license granted to Licensee
in Section 3.1 shall automatically convert to a fully paid-up license.

 

6.5.2
Termination Prior to Expiration. In the event this Agreement is terminated prior to expiration, then (a) all rights and
obligations of the Parties under and this Agreement shall terminate, except (i) the license granted in Section 3.1, (ii) Licensee’s
payment obligations and the reporting and audit rights set forth herein relating thereto and (iii) Section 6.6, shall, in each
of cases (i) through (iii), survive such termination.

 

6.6
Surviving Provisions.

 

6.6.1
Accrued Rights; Remedies. Termination, relinquishment or expiration of this Agreement for any reason shall be without prejudice
to any rights that shall have accrued to the benefit of any Party prior to such termination, relinquishment or expiration, and
any and all damages or remedies (whether in law or in equity) arising from any breach hereunder. Such termination, relinquishment
or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination of this Agreement.
Except as otherwise expressly set forth in this Agreement, the termination provisions of this ARTICLE 6 are in addition to any
other relief and remedies available to either Party under this Agreement and at applicable Law.

 

6.6.2
Survival. Notwithstanding any provision herein to the contrary, any rights or obligations otherwise accrued hereunder (including
any accrued payment obligations) shall survive the expiration or termination of this Agreement. Further, the rights and obligations
of the Parties set forth in the following Sections and Articles shall survive the expiration or termination of this Agreement,
in addition to those other terms and conditions that are expressly stated to survive termination or expiration of this Agreement:
Sections 4.3.2, 6.1.2, 6.5 and 6.6 and Articles 5 and 7.

 

    	11

     

    

 

ARTICLE
7

MISCELLANEOUS

 

7.1
Confidentiality; Publicity.

 

7.1.1
Confidentiality. Each Party agrees that a Party (the “Receiving Party”) receiving Confidential Information
of any other Party (the “Disclosing Party”) shall (a) maintain in confidence such Confidential Information
using not less than the efforts such Receiving Party uses to maintain in confidence its own proprietary information of similar
kind and value, but in no event less than a reasonable degree of efforts, (b) not disclose such Confidential Information to any
Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (c)
not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this
clause (c) shall not create or imply any rights or licenses not expressly granted under this Agreement). The obligations of confidentiality,
non-disclosure and non-use under this Section 7.1.1 shall be in full force during the Term and for a period of five (5) years
thereafter. Each Party, upon the request of the other Party, will return all copies of or destroy (and certify such destruction
in writing) the Confidential Information disclosed or transferred to it by the other Party pursuant to this Agreement, within
sixty (60) days of such request or, if earlier, the termination or expiration of this Agreement; provided however that a Party
may retain (i) Confidential Information of the other Party which expressly survives such termination pursuant to this Agreement,
and (ii) one (1) copy of all other Confidential Information in archives solely for the purpose of establishing the contents thereof.

 

7.1.2
Exceptions. The obligations in Section 7.1.1 shall not apply with respect to any portion of the Confidential Information
of the Disclosing Party that the Receiving Party can show by competent written proof:

 

(a)
was known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on
its use, prior to disclosure by the Disclosing Party;

 

(b)
is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and
without any obligation to keep it confidential or any restriction on its use;

 

(c)
is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is
disclosed to the Receiving Party, without any breach by the Receiving Party of its obligations hereunder; or

 

(d)
is independently developed by or for the Receiving Party or its Affiliates without reference to or reliance upon the Disclosing
Party’s Confidential Information.

 

7.1.3
Authorized Disclosure. Notwithstanding Section 7.1.1, the Receiving Party may disclose Confidential Information belonging
to the Disclosing Party, and Confidential Information deemed to belong to both the Disclosing Party and the Receiving Party, to
the extent (and only to the extent) such disclosure is reasonably necessary in the following instances:

 

    	12

     

    

 

(a)
subject to Section 7.1.5, complying with applicable Laws (including the rules and regulations of the U.S. Securities and Exchange
Commission (“SEC”) or any national securities exchange) and with judicial process, if in the reasonable opinion
of the Receiving Party’s counsel, such disclosure is necessary for such compliance;

 

(b)
disclosure of the other Party’s Confidential Information to any of its officers, employees, consultants, agents or Affiliates
or sublicensees (and in the case of Licensee, Sublicensees) if and only to the extent necessary to carry out its responsibilities
or exercise its rights under this Agreement; provided that each such disclose is bound by written confidentiality obligations
to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement;

 

(c)
disclosure, solely on a “need to know basis,” to (i) Affiliates, potential or actual research and development collaborators,
subcontractors, advisors (including attorneys and accountants), (ii) subject to Section 7.1.3(d), actual or potential acquirers,
investment bankers, investors, lenders, or other potential financial partners, and (iii) in each case of (i) and (ii), their and
each of the Parties’ respective directors, employees, contractors and agents; provided, that in all cases of (i), (ii) and
(iii), prior to any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and
non-use no less restrictive than the obligations set forth in this Section 7.1 (provided, however, that in the case of prospective
investment bankers, investors, lenders or other financial partners, the term of confidentiality may be shortened to three (3)
years from the date of disclosure and in the case of legal advisors, no written agreement shall be required), which for the avoidance
of doubt, will not permit use of such Confidential Information for any purpose except those permitted by this Agreement; provided,
however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who
receives Confidential Information pursuant to this Section 7.1.3(c) to treat such Confidential Information as required under this
Section 7.1; and

 

(d)
in the case of any disclosure of this Agreement to any actual or potential acquirer, or prospective investment bankers, investors,
lenders or other financial partners, such disclosure shall solely be in the form of the redacted version of this Agreement, which
version shall be agreed upon by the Parties in good faith; it being understood and agreed that only after negotiations with any
such Third Party have progressed so that such Party reasonably and in good faith believes it is in the final round of negotiations
with such Third Party regarding execution of a definitive agreement with such Third Party with respect to the proposed transaction,
only then may such Party provide an unredacted version of this Agreement to such Third Party.

 

If
and whenever any Confidential Information is disclosed in accordance with this Section 7.1.3, such disclosure shall not cause
any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure
of such information (other than by breach of this Agreement). Where reasonably possible and subject to Section 7.1.5, the Receiving
Party shall notify the Disclosing Party of the Receiving Party’s intent to make any disclosures pursuant to Section 7.1.3
sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may
deem appropriate to protect the confidentiality of the information, and the Receiving Party will provide reasonable assistance
to the Disclosing Party with respect thereto; provided that, in the event, the Receiving Party will use reasonable measures to
ensure confidential treatment of such information and shall only disclose such Confidential Information of the Disclosing Party
as is necessary to comply with such Laws or judicial process.

 

    	13

     

    

 

7.1.4
Terms of this Agreement. The Parties agree that this Agreement and all of the respective terms hereof shall be deemed to
be Confidential Information of Licensee and Celgene, and each Party agrees not to disclose any of them without the prior written
consent of the other Party, except that each Party may disclose any of them in accordance with the procedures of Section 7.1.3
(and the provisions related thereto, including, to the extent applicable, the provisions of Section 7.1.5) and 7.1.6.

 

7.1.5
Securities Filings. Each Party acknowledges and agrees that the other Party may submit this Agreement or any executed License
Agreement to the SEC or any national securities exchange in any jurisdiction (collectively the “Securities Regulators”),
and if a Party does submit this Agreement or any such License Agreement to any Securities Regulators, such Party agrees to
consult with the other Party with respect to the preparation and submission of, a confidential treatment request for such agreement.
Notwithstanding the foregoing, if a Party is required by applicable Law or any Securities Regulator to make a disclosure of the
terms of this Agreement or any License Agreement in a filing with or other submission to such Securities Regulator, and (a) such
Party has provided copies of the disclosure to the other Party as far in advance of such filing or other disclosure as is reasonably
practicable under the circumstances, (b) such Party has promptly notified the other Party in writing of such requirement and any
respective timing constraints, and (c) such Party has given the other Party a reasonable time under the circumstances from the
date of notice by such Party of the required disclosure to comment upon, request confidential treatment or approve such disclosure,
then such Party will have the right to make such public disclosure at the time and in the manner reasonably determined by its
counsel to be required by applicable Law. Notwithstanding anything to the contrary herein, it is hereby understood and agreed
that if a Party seeking to make a disclosure to a Securities Regulator as set forth in this Section 7.1.5, and the other Party
provides comments within the respective time periods or constraints specified herein or within the respective notice, the Party
seeking to make such disclosure or its counsel, as the case may be, will in good faith consider incorporating such comments.

 

7.1.6
Publicity. Upon or following the Effective Date, Licensee may issue the press release attached hereto as Exhibit C. In
all other cases, the issuance of any press release or other public statement by either Party or their respective Affiliates disclosing
any information relating to this Agreement shall be subject to the prior written consent of the other Party.

 

7.2
Warranties:, Disclaimer of Warranties.

 

7.2.1
Mutual Representations and Warranties. Each Party represents and warrants to the other Party that as of the Effective Date:
(a) it has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder; (ii) this
Agreement has been duly executed by it and is legally binding upon it, enforceable against such Party in accordance with its terms,
except as such enforceability may be subject to applicable bankruptcy, reorganization, insolvency, moratorium and similar Laws
affecting the enforcement of creditors’ rights generally and by general principles of equity; and (iii) the execution and
delivery by such Party of this Agreement does not conflict with the terms of any agreement, instrument or understanding, oral
or written, to which it is a party or by which it may be bound, nor violate any applicable Law.

 

    	14

     

    

 

7.2.2
Except as otherwise expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY
KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL
IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.

 

7.3
Assignment.

 

7.3.1
General. Either Party may assign this Agreement, or any rights or obligations hereunder in whole or in part, only to (a)
one or more Affiliates, provided, however, that in the event of any such assignment, the assigning party shall nevertheless remain
responsible for the performance of its obligations under this Agreement and shall guarantee the performance of its obligations
hereunder by such assignee; or (b) its successor in interest in connection with the merger, consolidation, or sale of all or substantially
all of its assets or that portion of its business pertaining to the subject matter of this Agreement.

 

7.3.2
All Other Assignments Null and Void. The terms of this Agreement will be binding upon and will inure to the benefit of
the successors, heirs, administrators and permitted assigns of the Parties. Any purported assignment in violation of this Section
7.3 will be null and void ab initio.

 

7.4
Choice of Law; Jurisdiction; Venue. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF NEW YORK, IRRESPECTIVE OF THE CHOICE OF LAWS PRINCIPLES OF THE STATE OF NEW YORK, AS TO ALL MATTERS,
INCLUDING MATTERS OF VALIDITY, CONSTRUCTION, EFFECT, ENFORCEABILITY, PERFORMANCE AND REMEDIES. Except as otherwise provided herein,
the sole jurisdiction, venue and dispute resolution procedure for all disputes, controversies or claims (whether in contract,
tort or otherwise) arising out of, relating to or otherwise by virtue of, this Agreement, breach of this Agreement or the transactions
contemplated by this Agreement shall be the United States District Court for the Southern District of New York, and the parties
to this Agreement hereby consent to the jurisdiction of such court and waive any objection to the venue of such proceeding. Each
of the parties agrees that process may be served upon it in the manner specified in Section 7.5 and irrevocably waives and covenants
not to assert or plead any objection which it might otherwise have to such jurisdiction, or to such manner of service of process.
WAIVER OF JURY TRIAL. EXCEPT AS LIMITED BY APPLICABLE LAW, EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY
IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF. The Parties hereby
acknowledge that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached and that the parties would not have any adequate remedy at law.
Accordingly, the Parties shall be entitled to an injunction or injunctions to prevent breaches or threatened breaches of this
Agreement and to enforce specifically the terms and provisions of this Agreement, in addition to any and all other rights and
remedies at law or in equity, and all such rights and remedies shall be cumulative.

 

    	15

     

    

 

7.5
Entire Agreement; Interpretation; Notice. This Agreement, together with the attached Exhibits, contains the entire agreement
by the Parties with respect to the subject matter hereof and supersedes any prior express or implied agreements, understandings
and representations, either oral or written, which may have related to the subject matter hereof in any way, and any and all term
sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties prior to the Effective Date.
When a reference is made in this Agreement to a section or article, such reference shall be to a section or article of this Agreement,
unless otherwise clearly indicated to the contrary. Whenever the words “include,” “includes” or “including”
are used in this Agreement they shall be deemed to be followed by the words “without limitation.” The words “hereof,”
“herein” and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer
to this Agreement as a whole and not to any particular provision of this Agreement, and annex, article, section, paragraph, exhibit
and schedule references are references to the annex, articles, sections, paragraphs, exhibits and schedules of this Agreement,
unless otherwise specified. The plural of any defined term shall have a meaning correlative to such defined term and words denoting
any gender shall include all genders and the neuter. Where a word or phrase is defined herein, each of its other grammatical forms
shall have a corresponding meaning. Any reference to a party to this Agreement or any other agreement or document contemplated
hereby shall include such party’s successors and permitted assigns. A reference to any legislation or to any provision of
any legislation shall include any modification, amendment, re-enactment thereof, any legislative provision substituted therefore
and all rules, regulations and statutory instruments issued or related to such legislation. The headings and captions in this
Agreement are for reference only and shall not be used in the construction or interpretation of this Agreement. The parties have
participated jointly in the negotiation and drafting of this Agreement. If any ambiguity or question of intent or interpretation
arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement. No prior draft of this Agreement
nor any course of performance or course of dealing shall be used in the interpretation or construction of this Agreement. No parole
evidence shall be introduced in the construction or interpretation of this Agreement unless the ambiguity or uncertainty in issue
is plainly discernible from a reading of this Agreement without consideration of any extrinsic evidence. Although the same or
similar subject matters may be addressed in different provisions of this Agreement, the parties intend that, except as reasonably
apparent on the face of the Agreement or as expressly provided in this Agreement, each such provision shall be read separately,
be given independent significance and not be construed as limiting any other provision of this Agreement (whether or not more
general or more specific in scope, substance or content). The doctrine of election of remedies shall not apply in constructing
or interpreting the remedies provisions of this Agreement or the equitable power of a court considering this Agreement or the
transactions contemplated hereby. Should any time period in this Agreement that is not tied to Business Days end on a day other
than a Business Day, such period will be deemed extended to the next occurring Business Day. All notices and other communications
under this Agreement shall be in writing and shall be deemed given when delivered personally, one Business Day after having been
dispatched by a nationally recognized overnight courier service or when sent via email to the Parties at the following addresses
(or at such other address for a Party as is specified by like notice):

 

    	16

     

    

 

If
to Celgene:

 

Celgene
Corporation

86
Morris Avenue

Summit,
NJ 07901

Attention:
Head of Business Development and General Counsel

 

If
to IRX:

 

IRX
Therapeutics, Inc.

140
W57th Street, Suite 3D

New
York, NY 10019

Attention:
Chief Financial Officer

 

Any
such notice shall be deemed given on the date received. A Party may add, delete, or change the person or address to which notices
should be sent at any time upon written notice delivered to the Party’s notices in accordance with this Section 7.5.

 

[Signature
Page Follows]

 

    	17

     

    

 

IN
WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Agreement to be executed by their respective
duly authorized officers as of the Effective Date.

 

	CELGENE, INC.	 	IRX THERAPEUTICS, INC.
	 	 	 	 	 
	By:	/s/
    Robert Hershberg	 	By:	/s/
    Mark Leucktenberger
	Name:	Robert
    Hershberg 	 	Name:	/s/
    Mark Leucktenberger
	Title:	EVP,
    Head of BD & Global Alliances	 	Title:	President
    and CEO

 

[Signature
page to License Agreement]

 

    	 

     

    

 

EXHIBIT
A

 

[***]

 

    	A-1

     

    

 

Exhibit
B

 

IRX
Patents

 

[***]

 

    	B-1

     

    

 

EXHIBIT
C

 

[Press
Release]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]